Literature DB >> 7537265

Functional interaction between c-Src and its mitotic target, Sam 68.

S J Taylor1, M Anafi, T Pawson, D Shalloway.   

Abstract

The c-Src tyrosine kinase phosphorylates and binds to a 68-kDa RNA-binding protein in mitotic cells. We have examined the mechanism and functional consequence of the interaction of c-Src with this protein, Sam 68 (Src associated in mitosis, 68 kDa). In whole cell homogenates, Sam 68 was the predominant substrate and binding partner of overexpressed c-Src. Mitotic, tyrosine-phosphorylated Sam 68 bound selectively to recombinant SH2 domains with significantly different affinities (c-Src approximately Ras GTPase activating protein > p85 alpha (amino-terminal) > Grb2 >> p85 alpha (COOH-terminal)). In vitro translated Sam 68 also bound selectively to recombinant SH3 domains, with the highest affinity for the Src and p85 alpha SH3 domains. SH3 binding was inhibited by specific Sam 68 peptides. In vitro translated Sam 68 bound directly to immobilized poly(U), and this was inhibited by binding of Src and p85 SH3 domains to Sam 68. The results suggest that the selection of Sam 68 as a mitotic target by c-Src is the result of highly specific interaction with SH2 and SH3 domains and that this interaction may modulate the RNA binding activity of Sam 68.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537265     DOI: 10.1074/jbc.270.17.10120

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  The interaction and colocalization of Sam68 with the splicing-associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59(fyn).

Authors:  A M Hartmann; O Nayler; F W Schwaiger; A Obermeier; S Stamm
Journal:  Mol Biol Cell       Date:  1999-11       Impact factor: 4.138

2.  A role for the GSG domain in localizing Sam68 to novel nuclear structures in cancer cell lines.

Authors:  T Chen; F M Boisvert; D P Bazett-Jones; S Richard
Journal:  Mol Biol Cell       Date:  1999-09       Impact factor: 4.138

3.  Association of human DEAD box protein DDX1 with a cleavage stimulation factor involved in 3'-end processing of pre-MRNA.

Authors:  S Bléoo; X Sun; M J Hendzel; J M Rowe; M Packer; R Godbout
Journal:  Mol Biol Cell       Date:  2001-10       Impact factor: 4.138

4.  Sam68 enhances the cytoplasmic utilization of intron-containing RNA and is functionally regulated by the nuclear kinase Sik/BRK.

Authors:  John H Coyle; Brian W Guzik; Yeou-Cherng Bor; Li Jin; Lucia Eisner-Smerage; Stephen J Taylor; David Rekosh; Marie-Louise Hammarskjöld
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

Review 5.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

6.  Clinical significance of Sam68 expression in endometrial carcinoma.

Authors:  Qingying Wang; Yue Li; Jianhong Zhou; Jie Liu; Jinlong Qin; Feng Xing; Jiawen Zhang; Jiajing Cheng
Journal:  Tumour Biol       Date:  2015-01-21

7.  Self-association of the single-KH-domain family members Sam68, GRP33, GLD-1, and Qk1: role of the KH domain.

Authors:  T Chen; B B Damaj; C Herrera; P Lasko; S Richard
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

8.  Tyrosine phosphorylation of QKI mediates developmental signals to regulate mRNA metabolism.

Authors:  Youyi Zhang; Zifan Lu; Li Ku; Yuntao Chen; Houping Wang; Yue Feng
Journal:  EMBO J       Date:  2003-04-15       Impact factor: 11.598

9.  Sam68 is tyrosine phosphorylated and recruited to signalling in peripheral blood mononuclear cells from HIV infected patients.

Authors:  S Najib; J Rodríguez-Baño; M J Ríos; M A Muniain; R Goberna; V Sánchez-Margalet
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

10.  Cooperative activation of Src family kinases by SH3 and SH2 ligands.

Authors:  Shalini S Yadav; W Todd Miller
Journal:  Cancer Lett       Date:  2007-08-24       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.